Irbesartan Hydrochlorothiazide Zentiva (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. This leads to relaxed blood vessels and reduced fluid retention, contributing to lower blood pressure when used together with hydrochlorothiazide.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s blood‑pressure goals, renal function, and overall health status. The prescriber will select the appropriate strength and frequency.

Safety data for Irbesartan/HCTZ in pregnancy are limited, and the product is generally not recommended unless the potential benefit outweighs the risk. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy agents, the Irbesartan/HCTZ combination offers dual mechanisms—vascular relaxation and diuresis—providing more potent blood‑pressure reduction. It may be preferred when a single agent does not achieve target pressures, but clinicians consider individual patient factors and potential side‑effect profiles.

Store the tablets at ambient temperature, below 25 °C, in the original packaging. Keep them away from moisture, heat and direct sunlight to maintain stability and potency throughout the shelf life.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe dehydration, electrolyte imbalances (especially low potassium), acute kidney injury, hyperkalemia, and rare cases of angioedema. Patients should report symptoms such as rapid weight loss, muscle weakness, swelling of the face or throat, or a sudden drop in blood pressure.

The combination should be avoided in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It is also contraindicated in severe renal impairment, anuria, and in patients with a history of angioedema related to ARB therapy.